ASTRAZEN.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 11:59):

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally...

Stats
Tagesvolumen	11 479.00
Durchschnittsvolumen	20 363.00
Marktkapitalisierung	135.65B
EPS	INR0 ( 2024-02-08 )
Nächstes Ertragsdatum	( INR0 ) 2024-05-28
Last Dividend	INR16.00 ( 2023-07-14 )
Next Dividend	INR0 ( N/A )
P/E	97.08
ATR14	INR7.31 (0.13%)

Volumen Korrelation

Lang: -0.24 (neutral)

Kurz: -0.54 (weak negative)

Signal:(49.51) Neutral

AstraZeneca Pharma India Korrelation

10 Am meisten positiv korreliert
SEYAIND.NS	0.834

10 Am meisten negativ korreliert
CONTROLPR.NS	-0.807

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

AstraZeneca Pharma India Korrelation - Währung/Rohstoff

0.45
( neutral )

0.36
( neutral )

0.79
( moderate )

-0.04
( neutral )

-0.27
( neutral )

-0.81
( strong negative )

AstraZeneca Pharma India Finanzdaten

Annual	2022
Umsatz:	INR10.03B
Bruttogewinn:	INR5.45B (54.37 %)
EPS:	INR39.72

FY	2022
Umsatz:	INR10.03B
Bruttogewinn:	INR5.45B (54.37 %)
EPS:	INR39.72

FY	2022
Umsatz:	INR8.06B
Bruttogewinn:	INR4.48B (55.63 %)
EPS:	INR24.60

FY	2021
Umsatz:	INR8.09B
Bruttogewinn:	INR4.78B (59.12 %)
EPS:	INR37.30

Financial Reports:

No articles found.

AstraZeneca Pharma India Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR8.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR16.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

AstraZeneca Pharma India Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.66 - low (54.78%) | Divividend Growth Potential Score: 2.22 - Decrease likely (55.55%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.70	2003-04-17
Last Dividend	INR16.00	2023-07-14
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR184.10	--
Avg. Dividend % Per Year	0.19%	--
Score	1.47	--
Div. Sustainability Score	4.66
Div.Growth Potential Score	2.22
Div. Directional Score	3.44	--

Next Divdend (Est)
(2024-09-25)

INR18.37 Estimate 2.96 %

Dividend Stability

0.24 Very Poor

Dividend Score

1.47

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR1.000	0.07%
2020	INR2.00	0.08%
2021	INR2.00	0.04%
2022	INR8.00	0.26%
2023	INR16.00	0.48%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUNDARMHLD.NS	Dividend Junior	2023-07-03	Annually	7	1.35%
NATIONALUM.NS	Dividend Knight	2023-09-15	Semi-Annually	26	4.12%
HLEGLAS.NS	Dividend Junior	2023-09-21	Annually	4	0.19%
CANTABIL.NS	Dividend Junior	2023-09-15	Annually	5	0.63%
RITES.NS	Dividend Knight	2023-09-08	Quarterly	7	3.95%
LAMBODHARA.NS	Dividend Junior	2023-09-14	Annually	10	0.87%
FORCEMOT.NS	Dividend Junior	2023-09-21	Annually	6	0.45%
APLAPOLLO.NS	Ex Dividend Junior	2023-09-01	Sporadic	13	0.07%
TATVA.NS	Dividend Junior	2023-09-08	Annually	3	0.04%
NUCLEUS.NS	Dividend Junior	2023-07-07	Annually	22	1.41%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.116	1.500	7.67	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.224	1.500	8.62	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	128.03	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
freeCashFlowPerShareTTM	9.89	2.00	5.06	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.518	1.000	4.71	4.71	[0.2 - 0.8]
operatingProfitMarginTTM	0.145	1.000	9.10	9.10	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.66

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	97.38	1.000	0.265	0	[1 - 100]
returnOnEquityTTM	0.224	2.50	9.11	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
dividendYielPercentageTTM	0.295	1.500	2.63	0	[0 - 0.4]
operatingCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-2.87	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0207	1.000	-1.984	0	[0.1 - 0.5]
Total Score				2.22

AstraZeneca Pharma India

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.